About Mereo BioPharma
Mereo BioPharma is a company based in London (United Kingdom) founded in 2015 by John Richard, Charles Sermon, and Denise Scots Knight. Mereo BioPharma has raised $119 million across 6 funding rounds from investors including Astrazeneca, Citadel and Orbimed. The company has 56 employees as of December 31, 2021. Mereo BioPharma has completed 1 acquisition, including Mereo BioPharma. Mereo BioPharma offers products and services including Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and Leflutrozole. Mereo BioPharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter London, United Kingdom
- Employees 56 as on 31 Dec, 2021
- Founders John Richard, Charles Sermon, Denise Scots Knight
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mereo Biopharma 1 Limited
- Date of Incorporation 18 Jun, 2015
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$119 M (USD)
in 6 rounds
-
Latest Funding Round
$70 M (USD), Post-IPO
Jun 04, 2020
-
Investors
Astrazeneca
& 11 more
-
Employee Count
56
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mereo BioPharma
Mereo BioPharma is a publicly listed company on the NASDAQ with ticker symbol MREO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mereo BioPharma
Mereo BioPharma offers a comprehensive portfolio of products and services, including Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and Leflutrozole.
Therapy for Osteogenesis Imperfecta in clinical development.
Treatment for alpha-1 antitrypsin deficiency lung disease.
Potential treatment in biopharmaceutical pipeline.
Development for rare disease applications.
Part of rare disease therapy pipeline.
Explored for rare disease treatment options.
People of Mereo BioPharma
Unlock access to complete
Unlock access to complete
Funding Insights of Mereo BioPharma
Mereo BioPharma has successfully raised a total of $119M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $70 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mereo BioPharma
Mereo BioPharma has secured backing from 12 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Astrazeneca, Citadel and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked |
Investor details for Mereo BioPharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mereo BioPharma
Mereo BioPharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Mereo BioPharma.
Investment portfolio details for Mereo BioPharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Monoclonal antibodies targeting cancer stem cell pathways are developed.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Mereo BioPharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Mereo BioPharma
Detailed financials for Mereo BioPharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mereo Biopharma Comparisons
Peer comparison for Mereo BioPharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mereo BioPharma
Mereo BioPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of Mereo BioPharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mereo Biopharma
Complete news archive for Mereo BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mereo BioPharma
Mereo BioPharma was founded in 2015.
Mereo BioPharma is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Denise Scots Knight is the current CEO of Mereo BioPharma. They have also founded this company.
Mereo BioPharma is a funded company, having raised a total of $119M across 6 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Mereo BioPharma is 56.
Developer of therapeutics for cancer and rare diseases. The companys pipeline includes Etigilimab for metastatic solid tumors, Alvelestat for the treatment of severe Alpha-1 Antitrypsin Deficiency and COVID-19, Setrusumab for the treatment of Osteogenesis Imperfecta, Navicixizumab for the treatment of platinum-resistant ovarian cancer, Acumapimod for the treatment of acute exacerbations of chronic obstructive pulmonary disease, and Leflutrozole for the treatment of male infertility associated with hypogonadotropic hypogonadism.
Mereo BioPharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Mereo BioPharma offers Setrusumab, Alvelestat, Etigilimab, Navicixizumab, and 2 more products and services.
Yes, Mereo BioPharma is publicly traded on NASDAQ under the ticker symbol MREO.
Mereo BioPharma has made 1 acquisition, including Mereo BioPharma.
Mereo BioPharma has 12 investors. Key investors include Astrazeneca, Citadel, Orbimed, Invesco Perpetual, and Woodford Investment Management.
The ticker symbol of Mereo BioPharma is MREO on NASDAQ.